Drug Insights

Laninolanor - Small Molecule Drug Targeting PPARα/PPARγ/PPARδ

15 August 2023
3 min read

Lanifibranor, a small-molecule drug targeting PPARα + PPARγ + PPARδ, was initially developed by AbbVie, Inc. On September 21, 2022, Inventiva announced that it had signed a license and cooperation agreement with CStone Pharmaceuticals for the development and commercialization of the pan-PPAR agonist, lanifibranor, for the treatment of non-alcoholic steatohepatitis (NASH) and potential other metabolic diseases for the Chinese population. In July 2023, the drug was concurrently granted Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations by the FDA. 

According to the "Synapse" database, the currently researched indications for this drug include fibrosis, non-alcoholic steatohepatitis, type 2 diabetes, systemic sclerosis, cirrhosis, and more. Among them, fibrosis has already entered Phase 3 clinical trials in multiple countries including the US, Italy, and Canada. For more detailed information.

This drug has recently been recognized as a rare breakthrough therapy for NASH. Moreover, on July 24, the NMPA plans to grant Lanifibranor breakthrough therapy certification.

Mechanism of Action

Lanifibranor can activate all three subtypes of PPAR: α, γ, δ. Preliminary studies suggest that lanifibranor can improve insulin sensitivity and macrophage activation, reduce liver fibrosis and inflammation gene expression. Its therapeutic effects exceed those of single or dual PPAR agonists.

Core Clinical Trials

In a phase 2b study (NCT03008070), the efficacy and safety of Lanifibranor for patients with non-alcoholic steatohepatitis were assessed. The trial included 247 participants, randomly assigned to the Lanifibranor 1200 mg group, the Lanifibranor 800 mg group, and the placebo group. The results showed that the fibrosis regression rate was 48% in the Lanifibranor 1200 mg group, 34% in the 800 mg group, and 29% in the placebo group. Furthermore, the NASH resolution rate was 49% in the Lanifibranor 1200 mg group, 39% in the 800 mg group, and 22% in the placebo group.

Competitive Landscape

Statistics show that there are currently eight pipeline drugs involving PPARα + PPARγ + PPARδ. Apart from Lanifibranor, no other Pan-PPAR drugs have made progress or terminated research and development.

FCN-159 - An Oral High-Efficiency Selective MEK1/2 Inhibitor
Drug Insights
4 min read
FCN-159 - An Oral High-Efficiency Selective MEK1/2 Inhibitor
15 August 2023
FCN-159 is an orally effective selective MEK1/2 inhibitor and a prospective targeted therapy drug for tumors mutated by BRAF or RAS.
Read →
Drug pipeline database guide for pipeline & marketed drug analysis
Feature Updates
4 min read
Drug pipeline database guide for pipeline & marketed drug analysis
15 August 2023
Synapse functions as an indispensable free drug pipeline database tool for pharmaceutical and biotech sectors, enhancing drug pipelines and marketed drugs by presenting analytical intelligence on a wide range of drug discovery and development.
Read →
Fruquintinib - A Small Molecule Drug Targeting VEGFR1/VEGFR2/VEGFR3
Drug Insights
3 min read
Fruquintinib - A Small Molecule Drug Targeting VEGFR1/VEGFR2/VEGFR3
14 August 2023
Fruquintinib is a small molecule drug targeting VEGFR1, VEGFR2, and VEGFR3. This drug was initially developed by Hutchison Whampoa Medicine (Shanghai) Co., Ltd.
Read →
Zenocutuzumab - A Bispecific Antibody Targeting HER2/HER3
Drug Insights
3 min read
Zenocutuzumab - A Bispecific Antibody Targeting HER2/HER3
15 August 2023
Zenocutuzumab is a bispecific antibody targeting HER2/HER3 developed by Merus NV. On July 7, 2023, the U.S. FDA granted Zenocutuzumab breakthrough therapy desig-nation for NRG1 fusion-positive non-small cell lung cancer.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.